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Abstract
Objective To determine survival and neonatal morbidity for babies born
between 22 and 26 weeks’ gestation in England during 2006, and to
evaluate changes in outcome since 1995 for babies born between 22
and 25 weeks’ gestation.
Design Prospective national cohort studies.
Setting Maternity and neonatal units in England.
Participants 3133 births between 22 and 26 weeks’ gestation in 2006;
666 admissions to neonatal units in 1995 and 1115 in 2006 of babies
born between 22 and 25 weeks’ gestation.
Main outcomemeasuresSurvival to discharge from hospital, pregnancy
and delivery outcomes, infant morbidity until discharge.
Results In 2006, survival of live born babies was 2% (n=3) for those
born at 22 weeks’ gestation, 19% (n=66) at 23 weeks, 40% (n=178) at
24 weeks, 66% (n=346) at 25 weeks, and 77% (n=448) at 26 weeks
(P<0.001). At discharge from hospital, 68% (n=705) of survivors had
bronchopulmonary dysplasia (receiving supplemental oxygen at 36
weeks postmenstrual age), 13% (n=135) had evidence of serious
abnormality on cerebral ultrasonography, and 16% (n=166) had laser
treatment for retinopathy of prematurity. For babies born between 22
and 25 weeks’ gestation from March to December, the number of
admissions for neonatal care increased by 44%, from 666 in 1995 to
959 in 2006. By 2006 adherence to evidence based practice associated
with improved outcome had significantly increased. Survival increased
from 40% to 53% (P<0.001) overall and at each week of gestation: by
9.5% (confidence interval −0.1% to 19%) at 23 weeks, 12% (4% to 20%)
at 24 weeks, and 16% (9% to 23%) at 25 weeks. The proportions of
babies surviving in 2006 with bronchopulmonary dysplasia, major cerebral
scan abnormality, or weight and/or head circumference <−2 SD were
similar to those in 1995, but the proportion treated for retinopathy of
prematurity had increased from 13% to 22% (P=0.006). Predictors of
mortality and morbidity were similar in both cohorts.
Conclusion Survival of babies born between 22 and 25 weeks’ gestation
has increased since 1995 but the pattern of major neonatal morbidity
and the proportion of survivors affected are unchanged. These
observations reflect an important increase in the number of preterm
survivors at risk of later health problems.
Introduction
Preterm birth is associated with increased rates of neonatal
mortality and long term morbidities such as respiratory
problems, learning difficulties, cerebral palsy, and behavioural
problems, that are highest in the most immature.1 2 This is an
important public health issue as rates of preterm birth are rising
in many European countries and are particularly high in the
United Kingdom.3 The first EPICure study collected data for
all births in the UK and Ireland before 26 completed weeks’
gestation for 10 months in 1995,4 with detailed information for
those babies admitted for intensive care. Outcomes for surviving
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children have been reported to the age of 11.5 Since 1995 there
has been emphasis on several evidence based interventions to
reduce neonatal morbidity. These include increased use of
antenatal corticosteroids to promote lung maturation,6 strategies
to avoid neonatal hypothermia at birth,7 increased use of
surfactant replacement,8 and reduction in the use of postnatal
corticosteroids given to prevent bronchopulmonary dysplasia
but now thought to be associated with increased cerebral palsy.9
From around 2001 neonatal services in England have been
organised into clinical “networks” aiming to centralise delivery
and intensive care for the most immature infants into tertiary
hospitals with greater experience and 24 hour access to neonatal
specialist staff.10 Regional population based data from the UK
show reduced mortality for births before 26 weeks’ gestation
since 1995.11 It is less clear whether there has been change in
survival without major morbidity. Reduced severe
developmental delay and disability were reported for cohorts
from Victoria, Australia, for babies with birth weights below
1000 g in 1997 and 2005.12 In hospital based populations of
babies born before 25 weeks’ gestation in the United States in
1999-2001 and 2002-04, however, there were no significant
changes either in survival or in the prevalence of
neurodevelopmental impairment.13
Information about the likelihood of survival and childhood
impairments is important when discussing clinical decisions
with parents and planning services and should be based on the
best available data. We have outcomes for births before 26
weeks’ gestation in England from the EPICure study of births
in 1995. To know whether these outcomes can be extrapolated
to babies born in 2006 and more recently requires an
understanding of whether the prediction of outcome based on
early findings has changed in relation to changes in clinical
practice.
EPICure 2 was designed to measure survival and morbidity
after extreme preterm birth in 2006 in England and to compare
outcomes with outcomes for children in the first EPICure cohort.
The first EPICure study recruited births up to and including 25
completed weeks of gestation (that is, up to 25 weeks and 6
days’ gestation). In recruitment for EPICure 2 this was extended
to include all births at 26 weeks gestational age (that is, 26
weeks and 0 days to 26 weeks and 6 days) both because of a
lack of reliable data for babies born at 26 weeks and because
babies at this gestation routinely receive active care at birth,
forming a useful comparator group. We report outcomes until
initial discharge from hospital for babies born in 2006 between
22 and 26 weeks’ gestation and compare outcomes for babies
born between 22 and 25 weeks in 1995 and 2006.
Methods
Data collection, completeness, and quality
Births in 2006
Details of all births reported between 22 and 26 weeks’
gestation, or more immature but with birth weight over 400 g,
were collected prospectively in all 182 maternity hospitals in
England. All low risk midwife led centres were contacted early
in 2007 to collect details of any births meeting these criteria.
To avoid duplication of national data collection we carried out
this data collection in collaboration with the Centre forMaternal
and Child Health Enquiries. Terminations of pregnancy have
been reported separately14 and, together with information on
births to mothers not usually resident in England, are excluded
from this analysis.
We identified contacts in the labour ward and neonatal unit of
each hospital to lead the data collection.Monthly logs of eligible
births were returned to the EPICure office for monitoring and
validation. A member of the study team visited hospitals to
collect and complete missing forms and data items. Data were
double entered on a bespoke database with intervariable and
intravariable range checks to facilitate the highest possible data
quality. National data based on gestation at birth were not
available at the time of data collection so final checks of
completeness were limited to those areas where gestational age
based data are routinely collected. The dataset used in 2006 was
based on that used in 1995; a complete list of items in the dataset
is provided in appendix 1.
Comparison between births in 1995 and 2006
In 1995 data enabling confirmation of gestational age were
collected only for those babies admitted for intensive care. Our
comparisons are therefore between admitted babies born between
22 and 25 weeks’ gestation from the 2006 cohort and, to
standardise the geographical area, the subset of 666 admitted
babies from the 1995 cohort who were born in England.
In 1995, cohort data collection was from 1 March to 31
December. Analyses for the 2006 cohort were run on the whole
year and then separately for 1 March to 31 December. There
were no large differences; the difference in survival was 0.7%,
and the largest difference for any other outcome was 1.3% for
treated retinopathy of prematurity. Data are therefore presented
for the whole year for 2006 and the 10 month period in 1995.
Gestational age
For both cohorts we based the estimation of gestational age on
accepted current best practice. In the 2006 cohort, the earliest
ultrasound dating scan was used and, in the absence of any scan,
the date of the last menstrual period if it was certain.15 In the
absence of either scan or certain dates, we based gestation on
clinical estimation. In 1995 we based gestation on date of last
menstrual period unless a dating ultrasound scan performed
before 20 weeks’ gestation was discrepant by over 14 days.
Recalculation of gestational age of births in 2006 with the
algorithm used in 1995 resulted in a median increase in gestation
of 0.2 days and a reduction of total births estimated to be
between 22 and 26 weeks’ gestation from 3133 to 3088. As
survival and major morbidities were within SD 0.5% of each
other, we used the 2006 estimate throughout.
Principal outcomes
Survival
We measured survival for both cohorts to discharge from
hospital. In 2006 survival was calculated based on babies alive
at the onset of labour, babies born alive, babies admitted for
intensive care, and babies who survived seven days or more.
The population alive at the onset of labour was defined by the
documented presence of a fetal heart rate either when labour
was first diagnosed or caesarean section started or by live birth.
In 1995 survival was based on admissions and those surviving
seven days or more.
Morbidity
For babies surviving to discharge from hospital we recorded
continued oxygen supplementation at 36 weeks’ postmenstrual
age (bronchopulmonary dysplasia), findings on cerebral
ultrasonography, treated retinopathy of prematurity, surgically
treated necrotising enterocolitis, and growth (weight and head
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circumference) using the same definitions as in 1995.4 For 2006
births we additionally recorded details of infections with positive
results on blood culture and the severity of both
bronchopulmonary dysplasia (moderate disease: no mechanical
support and receiving less than 30% or ≤0.1 L/minute oxygen;
severe disease: mechanical support or higher oxygen
concentrations, observations made at 36 weeks’ postmenstrual
age)16 and retinopathy of prematurity (stages I-V).17 Findings
on cerebral ultrasonography are presented for the last scan data
that were available.
Survival without major morbidity was defined as survival to
discharge without severe changes on cerebral ultrasonography
(no ventrigulomegaly, echodense haemorrhagic parenchymal
infarction, porencephaly, or periventricular leucomalacia ) on
any scan, “severe” bronchopulmonary dysplasia,16 retinopathy
of prematurity ≥stage 3, or laparotomy for necrotising
enterocolitis.
Determinants of death and major morbidity
Wedeveloped predictionmodels using those items knownwithin
24 hours of birth that had been used in the analysis of the 1995
cohort.4 These models were used to investigate any changes
between 1995 and 2006 (cohort effect) in the survival of
admitted babies and major morbidity (major cerebral injury on
ultrasonography, bronchopulmonary dysplasia, continued use
of supplementary oxygen at 40 weeks’ postmenstrual age, and
treated retinopathy of prematurity).
Statistical analysis
Outcomeswere summarised as proportions, means, andmedians,
as appropriate.We used logistic, linear, and centile regressions,
respectively, to investigate the effect of gestational age (in
decimal weeks). For each week of gestation, we report exact
95% binomial confidence intervals of percentages and
percentage differences.
In the prediction models we used interaction terms to test
whether the associations of variables with outcomes were
different in the two cohorts. Any unexplained differences
between 1995 and 2006 were tested using “cohort” as a variable,
thus cohort is included in all the models. We used multivariable
logistic regression with a manual forward stepwise procedure
with replacement.
Stata statistical software (release 10.1; College Station, TX)
was used for all analyses and Kaplan-Meier survival curves. No
allowance was made for multiple tests, and significance was set
at P≤0.05.
Results
2006 cohort
A total of 3378 births were reported to the study centre.
Consideration of ultrasound scans andmenstrual dates confirmed
the gestation of 236 to be outside the range 22-26 weeks. Data
for nine other births were excluded, two at parental request and
seven, all of whom were either stillborn or died in the delivery
room, because there was inadequate information to determine
gestational age. The 3133 births in which gestation was
confirmed as between 22 and 26 weeks form the basis of our
analysis (table 1⇓). One baby was stillborn in a midwife led
maternity unit, 34 (19 live births) were born at home, and 27
(19 live births) were born elsewhere outside the hospital.
For 3039 (97%) fetuses, gestation was confirmed by
ultrasonography; the median gestation at the first dating scan
was 12 weeks and 4 days (interquartile range 11 weeks 1 day-14
weeks 5 days). Of the 94 remaining, menstrual dates were certain
for 16 and the gestational age for 78 was agreed by clinical
assessment; in three of these the paediatricians revised the
obstetric assessment. Validation of the data for the East
Midlands and Yorkshire regions with data from the neonatal
survey18 indicated a match for over 98% cases before the final
completion of the cohort.
Of the total of 3133 babies, the proportion known to be alive at
the onset of labour (n=2326) ranged from 57% (n=272) at 22
weeks’ gestation to 81% (n=594) at 26 weeks, (P<0.001 table
1⇓). Of 1099 stillbirths, 715 were antepartum and 292 were
intrapartum; the time of fetal death of the 92 other was unknown.
Status at delivery and care at birth
Of the 2326 babies known to be alive at the onset of labour,
2034 were born alive; the proportion ranged from 56% (n=152)
at 22 weeks’ gestation to 98% (n=580) at 26 weeks (P<0.001;
table 1⇓). The proportion of liveborn babies for whom active
stabilisation was withheld at birth decreased with increasing
gestation: 73% (111/152) at 22 weeks, 16% (55/338) at 23
weeks, and <2% (23/1535) at 24-26 weeks (table 1⇓). Of the
78 babies born after 23 completed weeks for whom stabilisation
was withheld, six (8%) had a potentially lethal malformation
known before, or apparent at, birth. Three babies were admitted
to a neonatal unit for palliative care; all died within 24 hours of
admission.
Of the liveborn babies offered stabilisation, 95% (1751/1838)
had endotracheal intubation and 72% (1303/1810) were treated
with surfactant in the delivery room. Delivery room surfactant
use increased linearly with gestational age from 46% (19/41)
at 22 weeks’ gestation through 66% (183/276) at 23 weeks to
77% (435/565) at 26 weeks (P<0.001). Occlusive wrapping to
prevent hypothermia was applied at birth to 62% (1176/1891)
of liveborn babies, increasing from 16% (24/148) at 22 weeks’
gestation through 53% (169/321) at 23 weeks to 72% (376/525)
at 26 weeks (P<0.001). The frequency of hypothermia at
admission reduced with increasing gestational age (table 1⇓),
even after adjustment for the use of occlusive wrapping: odds
ratio 0.54 per week (confidence interval 0.46 to 0.62). Full
details of birth weight for liveborn babies and those admitted
for neonatal intensive care by gestation, sex, and plurality are
provided in appendices 2 and 3.
Survival
Survival to 28 days and to discharge from hospital rose with
increasing gestational age (table 1⇓). For the lower gestational
ages, because death was more common in the delivery room,
there are important differences in survival to 28 days and to
discharge from hospital when it is expressed using admissions
rather than live births as the denominator. In 2006, babies died
on average 6.7 days (confidence interval 4 to 9 days) later per
additional week of gestational age (fig 1⇓). Median length of
stay in hospital for all survivors was 102 days (interquartile
range 86-113 days), decreasing from 124 days at 22 weeks’
gestation to 134 days at 23 weeks and 91 days at 26 weeks
(P<0.001; table 1⇓).
Interventions
Antenatal steroids—Of liveborn babies, 76% had been exposed
to antenatal steroids, increasing from 14% at 22 weeks’ gestation
to 58% at 23 weeks, 84% at 24 weeks, 88% at 25 weeks, and
86% at 26 weeks; 46% overall received a complete course.
Between 24 and 26 weeks’ gestation, 55% of babies admitted
to neonatal intensive care received a complete course of
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antenatal steroids compared with 30% at 23 weeks’ gestation;
table 1⇓).
Surfactant—Of the 1281 admitted babies known to have been
treated with surfactant replacement in the delivery room, 931
(72%) received at least one further dose after admission. A
further 361 of the 377 babies who did not receive surfactant in
the delivery room were treated after admission, so that 99% of
babies admitted received some surfactant treatment.
Nutrition—All but one of the surviving babies received
parenteral nutrition in the days after birth; 96% received
maternal breast milk at some time and 42% continued to receive
some breast milk at discharge from hospital. Rates of breast
feeding did not vary significantly with gestational age.
Postnatal steroids—Steroids were used to aid the weaning of
babies from ventilation in 16% (161/1039) of survivors (21%
(122/593) born before 26 weeks of gestation), starting at a
median age of 29 days (interquartile range 20-45) and given for
a median of 12 days (8-20). No baby was started on steroids for
this indication within the first seven days. Of the surviving
treated babies, 150 (94%) were prescribed dexamethasone:
median starting dose 0.2 mg/kg/day (interquartile range
0.15-0.5). Steroid use was more common at lower gestational
ages (P<0.001); the timing of commencement, duration of use,
and starting dose did not change with gestation.
Major morbidity in survivors to discharge
Respiratory morbidity—Of the 761 babies who were still alive
at 36 weeks postmenstrual age and still receiving supplementary
oxygen, 293 (39%) were classified as having moderate and 468
(61%) as severe bronchopulmonary dysplasia; three (1%) of the
moderate group and 44 (9%) of the severe group died without
leaving hospital. Of the survivors, 36% of the moderate and
62% of the severe group were discharged home with
supplementary oxygen.
Findings on cerebral ultrasonography—Unlike the other major
morbidities, the proportion of surviving babies who had a severe
abnormality reported on cerebral ultrasonography (13%, 95%
confidence interval 11% to 15%) was not related to gestational
age (table 2⇓).
Treated retinopathy of prematurity—Of the 166 surviving babies
who had laser treatment for retinopathy, 150 (90%) had stage
3 to stage 5 disease, and 162 (98%) had both eyes treated.
Laparotomy for necrotising enterocolitis—Laparotomies for
necrotising enterocolitis were performed in 79 (8%) surviving
babies. Details were not collected for episodes of necrotising
enterocolitis treated medically.
Overall 423 (41%) of survivors to discharge from hospital had
no reported major morbidity.
Comparison of outcomes for children born in
1995 and 2006 between 22 and 25 weeks’
gestation
Characteristics of admitted babies
Table 3⇓ gives comparative characteristics for the two cohorts.
The number of admissions for neonatal care of babies born from
March to December with gestational age between 22 and 25
weeks increased by 44% from 666 in 1995 to 959 in 2006. The
numbers of admissions varied by ethnic group, being higher for
babies born to Afro-Caribbean women and those from the Indian
subcontinent, so that the proportion of babies born to white
women decreased significantly (table 3).
From 1995 to 2006, the proportions of admitted babies born
after exposure to tocolytics and antenatal steroid increased, as
did reports of birth after a clinical diagnosis of chorioamnionitis,
while the prevalence of antepartum haemorrhage decreased. In
contrast, the proportion of singleton births, boys, and births by
caesarean section, both before and after the onset of labour, and
the distribution of birth weight by gestation were similar
between the two cohorts. Improved early condition of babies
born in 2006 was reflected in more having a heart rate over 100
beats per minute by five minutes, many fewer having admission
temperatures below 35°C, and lower median and mean clinical
risk index for babies (CRIB I) scores19 (table 3).⇓
Changes in survival
Survival to discharge from hospital for all admitted babies born
between 22 and 25 weeks’ gestation increased from 40%
(266/666) in 1995 to 53% (593/1115) in 2006, an increase of
13% (95% confidence interval 8% to 18%). Survival increased
at each week of gestation: by 9.5% (−0.1% to 19%) at 23 weeks,
12% (4% to 20%) at 24 weeks, and 16% (9% to 23%) at 25
weeks. This improved survival reflects the greater numbers of
babies surviving the first week after birth; the probability of
survival for babies at each week of gestation for those who
survived the first seven days was no different between the two
cohorts (fig 1).⇓
The median age at death in 2006 was 7 days, compared with 2
days in 1995; this is reflected in changes in the reported principal
cause of death in the babies who died: fewer deaths in 2006
were attributed to very early respiratory failure (pulmonary
insufficiency) and more to later complications of prematurity:
infection and necrotising enterocolitis (table 4⇓). Expressed as
a proportion of those alive on the seventh day, in 2006 death
from infection was 4% higher (95% confidence interval 0.5%
to 7%) and death from necrotising enterocolitis was 4% (2% to
6%) higher.
Hospital stay
The median length of stay in hospital for all survivors decreased
from 119 to 111 days (−8 days, 95% confidence interval −15
to −1 day); there was no change at 23 weeks’ gestation, a
decrease of 16 days at 24 weeks, and a decrease of 10 days at
25 weeks
Changes in neonatal morbidities
The prevalence of major morbidities in survivors in 2006 was
strikingly similar to 1995, with no differences in the proportions
with bronchopulmonary dysplasia, major cerebral injury
(ventriculomegaly, haemorrhagic parenchymal infarcts, or
parenchymal cysts) on the last available ultrasound scan (fig
2⇓), or of the decrease in the SD score for birth weight and
occipitofrontal circumference between birth and the expected
date of delivery (fig 3⇓). In contrast, the proportion of babies
discharged while still receiving supplementary oxygen (41%)
had increased by 7% (95% confidence interval −0.2% to 14%)
and the number who had laser treatment for retinopathy of
prematurity increased overall by 8% (3% to 13%; fig 2), this
difference was unaffected by gestational age.
Determinants of outcomes
The univariable associations were strikingly similar between
the two cohorts (see appendix 3). The most notable changes
were, firstly, the weakening of the relation between hypothermia
and death and, secondly, the lack of association between transfer
after birth with either severe abnormality on cerebral
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ultrasonography or prolonged requirement for oxygen. This
occurred despite an increased proportion of babies being
transferred within 24 hours of birth (table 3⇓). Antepartum
haemorrhage and CRIB I score showed different associations
in the two cohorts (see appendix 3). In the multivariable
prediction models, the perinatal variables in table 5⇓ were
significantly associated with one or more adverse outcome in
the combined cohorts and, with the exception of CRIB I score,
similarly when we considered each cohort separately. The
association between CRIB I score and death before discharge
was different between the two cohorts (odds ratio 0.93, 95%
confidence interval 0.97 to 0.99).
Two variables, neither of which was predictive with any
outcome in the combined cohorts, had significant associations
in one cohort when we considered them independently: transfer
within 24 hours of birth with severe abnormality on cerebral
ultrasonography in 1995 and antepartum haemorrhage with
survival in 2006. CRIB I score was associated with treated
retinopathy of prematurity in 2006 (odds ratio 1.10, 95%
confidence interval 1.02 to 1.18) but not in 1995.
The effect of cohort (table 5⇓) describes the risk of adverse
outcomes after adjustment for the condition of the baby in the
first 24 hours. For each outcome considered the risk was greater
in 2006 but only significantly so for treated retinopathy of
prematurity, suggesting that the improvement observed in
survival relates to improved early condition rather than to any
later factors.
Discussion
This study tracking outcomes of extremely preterm births in a
large geographically defined population showed improved
survival in 2006 compared with 1995 and several markers of
improved clinical practice. Despite this, the pattern of major
short termmorbidities and the associations between early clinical
items and adverse outcomes were similar.
EPICure 2 represents the first opportunity to report the changes
over time for perinatal and neonatal outcomes of a whole
country’s extremely preterm births. Planning support for
survivors of preterm birth requires an understanding of their
needs through childhood and adolescence into adult life. The
survivors from the first EPICure study, who were born in 1995,
form the largest reported population based cohort of extremely
preterm survivors; their follow-up has documented a range of
problems associated with preterm birth with lifelong
implications.5 20-23 EPICure 2 provides not only more recent
information but also the opportunity to study any changes in
the pattern of morbidity in survivors so that we can better
understand whether the longer term outcomes of the 1995
EPICure cohort are valid for babies born more recently.
We decided to limit the study to England for practical reasons
in anticipation of around 3500 births and 1650 admissions; in
1995 there had been no differences inmajor morbidities between
England and the other UK countries and Ireland. We included
births at a gestational age of 26 weeks in 2006 because of lack
of population based data for those babies and because such
babies are routinely offered intensive care, thus providing a
useful comparator group. We found no stepwise differences in
outcome between 25 and 26 weeks, rather a continuum of
morbidity-free survival across the gestation range.
The rates of preterm birth in the UK, while lower than in the
US, seem to be higher than in other European countries.3 The
significant increase in admissions before 26 weeks’ gestation
between the two cohorts needs to be better understood. In the
East Midlands Region of the UK, there was no increase in
extremely preterm admissions over the same time period,11
suggesting that there might be geographical variation. The
change in the ethnicity profile between the two cohorts is
difficult to interpret and takes no account of new waves of
immigration over this period, which covers the incorporation
of Eastern European countries in to the European Union with
associated economic migration into the UK; details of the
country of birth of the mother were not collected.
Overall survival in 2006 has increased since 1995, although not
significantly for births before 24 weeks’ gestation. This change
results from improved survival to the end of the first week, with
little difference thereafter. There is evidence of increased
adherence to evidence based practice in 2006, which could
account for improved condition of babies shortly after birth and
explain improved outcomes in the first week. The prevalence
of major morbidities in survivors, however, seems not to have
improved either when evaluated alone or after adjustment for
status within 24 hours of birth.
The apparent absence of improved survival in 2006 after the
first week is clinically important. Increased survival in the first
week could result in a population entering the second week at
higher risk of complications because of the survival of babies
who would previously have died. This is supported by increased
reporting of sepsis confirmed by blood culture and necrotising
enterocolitis as the primary cause of death in those surviving
the first week. Set against this, the lack of improvement in
somatic or head growth over the admission to neonatal intensive
care and the high rates of nosocomial infection reported in 2006
emphasise the urgency of developing safe and effective
strategies to improve early growth and prevent late infective
complications if further improvement in outcome is to be
achieved. In this context three aspects of care after admission
are noteworthy.
Firstly, from around 2003 the historical dispersed pattern of
provision of neonatal intensive care in England was reorganised
into networks with designated tertiary neonatal intensive care
units and improved access to dedicated postnatal transfer
services.24Despite encouragement of antenatal maternal transfer,
42% of live births at less than 26 weeks’ gestation in 2006 took
place outside the tertiary centres, and the proportion of babies
transferred within 24 hours of birth for intensive care had
increased significantly since 1995 (table 3⇓). Perhaps because
of better trained and equipped transport teams, however, babies
transferred in 2006 did not show the adverse outcomes
associated with transfer seen in 1995 (table 5).⇓
Secondly, in 2006 the use of postnatal steroid in survivors
declined from 71% to 21% and median length of treatment
declined from 21 to 12 days. In the 1995 cohort this was
associated in a dose dependent manner with severe motor
impairment at 30 months.25 Furthermore, it is likely that the
median starting dose (0.2 mg/kg/day) is lower and the overall
exposure to steroid greatly reduced.
Thirdly, the use of any maternal breast milk in survivors,
associated in 1995 with improved psychomotor developmental
index at 30 months,22 increased in 2006 for those born before
26 weeks from 86% to 96%. In 2006, 43% of all surviving
babies were receiving breast milk at discharge.
The emerging picture would seem to favour improved outcomes
and yet the pattern of major neonatal morbidities (fig 2⇓) is
strikingly similar to that in 1995. The observed increase in
treated retinopathy of prematurity might represent a change of
practice, with improved access to retinal screening and
ophthalmologists recommending treatment at earlier stages of
disease. Likewise the observed increase in the number of babies
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being discharged while still receiving supplementary oxygen,
which is associated with earlier discharge from hospital, is likely
to represent improved access to community nursing support.
Neither explanation can be confirmed. Some of the variation in
the strength of associations apparent in the analyses is probably
because of the increased size of the 2006 cohort. A small change
in reporting in 2006 to distinguish antepartum haemorrhage
from placental abruption could explain the differential effect in
the two cohorts, and different clinical indications for treatment
of retinopathy could account for the altered association with
CRIB I score. The most striking outcome of these analyses,
however, is the consistency between the two cohorts and the
lack of evidence, after adjustment for the condition of the baby
shortly after birth, of improved survival or changed proportion
of survivors with either bronchopulmonary dysplasia or severe
abnormality on cerebral ultrasonography.
Clinical condition around the time of preterm birth is
increasingly understood to be a critical determinant of later
outcome.26 27 28 The consistency of the predictive models for
short term outcomes across the two EPICure cohorts suggests
that early predictors of outcomes in the 1995 cohort25will remain
predictive of longer term outcomes in the 2006 cohort.
In the context of other population based studies, direct
international comparisons are complicated by a lack of
standardised data collection. In a review including population
based reports of live births before 26 weeks’ gestation between
1995 and 2000,2 survival for the 1995 EPICure cohort seemed
to be the lowest, with the highest being from the northern part
of Sweden. This was attributed to a positive approach on the
part of both obstetricians and neonatologists with centralisation
of specialist services and high rates of caesarean section and
provision of neonatal intensive care.29 Subsequently the
EXPRESS study reported outcomes for 1011 births between 22
and 26 weeks’ gestation from the whole of Sweden for 2004-07,
with high survival at 12 months of age (70% of live births
overall, 53% born at 23 weeks, and 85% born at 26 weeks).30
We derived a definition of survival without major morbidity
for the EPICure 2006 cohort (table 2⇓) that is close to that used
in the EXPRESS study. Three of the babies who survived to
discharge, all of whom had major morbidity, died before their
first birthday. Despite such big differences in survival between
the two studies, the proportions of survivors without major
morbidity at one year in the EPICure 2 (41%, 95% confidence
interval 38% to 44%) and EXPRESS cohorts (45%, 41% to
50%) are similar.
Strengths of this study
The main strengths of this study are the size of the cohort,
representing a complete national cohort and recruited with high
ascertainment, and the quality of the data. All the babies were
born over a short time span, and our findings are relevant to
current practice. We received high cooperation from clinical
staff and are confident that ascertainment is virtually 100%. As
in the first study, all outlying and ambiguous data were checked
with contributors and further checked and corrected if necessary
at analysis. All data were double entered to check validity, in
contrast with the first study in which only 10% of data were
double entered.
We constrained our definitions of variables to match those of
the original study, and it was therefore possible to track changes
over time in clinical outcomes for this important vulnerable
population. Additionally, in 2006 enhanced data were collected
for all births, including stillbirths, so that outcomes could
reliably be expressed with relevant denominators including total
and live births and that further analyses could be undertaken to
understand determinants of condition at birth.
Limitations of the study
In 2006 it was not possible to collect these data electronically
because of patchy access to suitable computer facilities in
maternity and neonatal units, and yet all data items would be
expected to be available in the clinical record. The data
collection imposed a huge volume of additional work for clinical
staff and the checking of missing and ambiguous data is time
consuming and causes delay in closing of databases and analysis.
Since 2006, standardised electronic data have been collected in
English neonatal units, and this is now almost universal with
developing systems for the centralisation of data for audit and
research purposes.31 In future, electronic data captured for
routine clinical purposes should be of sufficient quality to
provide the basis for such studies, making them easier, less
expensive, and with results more readily available.
Gestational age is the most important predictor of survival for
the preterm baby and is favoured over birth weight as the
principal criterion for defining preterm cohorts. Nonetheless,
the determination of gestation remains imprecise. Best practice
for the estimate of gestation has changed over time;
consequently a different algorithm was used for each cohort.
This produced only minor differences in survival and major
morbidities, so for this reason and for ease of comparison with
other contemporary cohorts, we have presented outcomes for
the 2006 cohort with the contemporary algorithm.
Recent changes in neonatal practice
It is important to consider whether changes since 2006 might
have affected our findings. We are not aware of any reliable
data supporting further centralisation of delivery of babies born
before 27 weeks’ gestation in England or further improvement
in the condition of babies at birth. Interest continues in
minimising overexpansion of the lungs at birth and exposure to
unnecessarily high concentrations of oxygen.32 Randomised
trials have confirmed that the early application of nasal
continuous positive airway pressure (CPAP) to babies who
establish breathing spontaneously33 34 and, more recently, the
use of nebulised surfactant replacement35 can reduce the number
of babies who require endotracheal intubation. The role of
probiotics to prevent sepsis, necrotising enterocolitis, and death
remains controversial.36 Few babies born between 22 and 26
weeks’ gestation are included in the published trials of any of
these interventions, and longer term outcomes have not been
reported. Other factors that might in time feed through to better
outcomes include collaborative quality improvement initiatives,37
which through the introduction of standardised “care bundles,”
have been shown to be effective in reducing catheter related
sepsis in newborn infants.38 Given the lack of change in the
pattern of morbidity in surviving extremely preterm babies
between 1995 and 2006, a period when evidence based practice
was increasing, it seems unlikely that it has changed since 2006.
Summary
Our findings support the validity of using longer term outcome
data from the 1995 EPICure cohort when considering the
prognosis for contemporary babies. Though the pattern of major
short term morbidities and the associations of early clinical
items with adverse outcomes were similar, there has been a 44%
increase in the numbers of extremely immature babies being
admitted to our neonatal intensive care units. Increased
admissions, increased survival, and unchanged rates of major
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adverse outcomes suggest that the while the total number of
children surviving extremely preterm birth free from
impairments will rise, so will the number with long term health
problems. This represents an important increase in workload
for health, educational, and social services.
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What is already known on this topic
Mortality and morbidity are high after extremely preterm birth
Children who survive preterm birth experience a range of problems requiring additional help from health, educational, and social services
and with lifelong implications
What this study adds
Between 1995 and 2006, the number of admissions to neonatal intensive care units of babies born between 22 and 25 weeks’ gestation
increased by 44%
Survival of babies born between 22 and 25 weeks’ gestation has increased, but the proportion of survivors with major neonatal morbidity
is unchanged
These changes suggest that the total number of children in the community with lifelong health problems attributable to extremely preterm
birth will rise
Tables
Table 1| Perinatal characteristics of births between 22 and 26 weeks’ gestation in 2006 and survival to discharge from hospital. Figures
are numbers (percentages, as shown), unless stated otherwise
P value*
Gestational age (weeks)
22-262625242322
Births (including all stillbirths)
—3133733692636594478Total
—715131140133153158Antepartum stillbirths
—2326 (74)594 (81)550 (80)494 (78)416 (70)272 (57)Alive at onset of labour† (%
total births)
—29214295277120Intrapartum stillbirths
—928292548Time of intrauterine death
unknown
Live births
<0.0012034 (87)580 (98)521 (95)442 (89)339 (81)152 (56)Total (% alive at onset of
labour)
<0.0011179 (58%)350 (60%)343 (66)254 (58)163 (48)69 (45)Birth in hospital with
designated tertiary neonatal
intensive care unit (% live
births)
<0.001189/2031 (9)3/574 (1)4/520 (1)16/441 (4)55/338 (16)111/152 (73)Active stabilisation withheld (%
live births)
—300210Admissions for palliative care
Admissions for intensive care
<0.0011686 (83)571 (98)498 (96)381 (86)217 (64)19 (13)Total (% live births)
<0.0011397 (83)486 (86)437 (88)326 (86)140 (65)8 (42)Any antenatal steroid (% of
admissions)
<0.001471 (28)250 (44)153 (31)55 (14)12 (6)1 (5)Caesarean section (% of
admissions)
<0.001750 (639-870)879 (787-970)779 (699-850)671 (610-730)600 (548-649)540 (509-574)Median (IQR) birth weight (g)‡
0.661669/1686 (99)567/571 (99)490/498 (98)379/381 (81)215/217 (99)18/19 (95)Surfactant given at any time (%
admissions )
<0.001224/1653 (14)37/562 (7)58/495 (12)64/374 (17)60/206 (29)5/16 (31)Admission temperature <35°C
(% admissions)
<0.001299/1686 (18)74/571 (13)85/498 (17)84/381 (22)53/217 (24)3/19 (16)Total transferred§ within 24
hours (% admissions)
Survival to 28 days
—1169472378226885Total
<0.00157 (55 to 60)81 (78 to 85)73 (68 to 76)51 (46 to 56)26 (21 to 31)3 (1 to 8)% of live births (95% CI)
<0.00169 (67 to 72)83 (79 to 86)76 (72 to 80)59 (54 to 64)41 (34 to 47)26 (9 to 51)% of admissions (95% CI)
Survival to discharge
—1041448346178663Total
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Table 1 (continued)
P value*
Gestational age (weeks)
22-262625242322
<0.00151 (49 to 53)77 (73 to 81)66 (62 to 71)40 (36 to 45)19 (15 to 24)2 (0 to 6)% of live births (95% CI)
<0.00162 (59 to 64)78 (75 to 82)69 (65 to 74)47 (41 to 52)30 (24 to 37)16 (3 to 40)% of admissions (95% CI)
<0.001102 (86-113 )91 (80-113 )102 (87-1221 )116 (98-141 )134 (115-171 )124 (119-252 )Median age (days) at discharge
(IQR)
IQR=interquartile range.
*P value for association of gestational age using either logistic regression or regression with gestational age in days.
†Includes all births by caesarean section when fetus was known to be alive at beginning of procedure.
‡Missing for one baby born at 23 weeks’ gestation. Birth weights for subgroups of live births and admissions by multiple birth, sex, and gestational age are given
as appendix 2 (live births) and 3 (admissions).
§Transferred to another hospital for ongoing care within 24 hours of birth.
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Table 2| Major neonatal morbidity among babies born between 22 and 26 weeks’ gestation who survived to discharge, England, 2006.
Figures are numbers (percentage, 95% confidence interval)
P value*
Gestational age (weeks)
22-262625242322
1041448346178663Total survivors
Major morbidities
<0.001705 (68, 65 to 71)272 (61, 56 to 66)231 (67, 62 to 72)142 (80, 73 to 85)57 (86, 76 to 94)3 (100, 29 to 100)Bronchpulmonary dysplasia
(supplementary oxygen at
36 weeks postmenstrual
age)
<0.001426 (41, 38 to 44)151 (34, 29 to 38)136 (39, 34 to 45)95 (53, 46 to 61)42 (64, 51 to 75)2 (67, 9 to 99)Severe bronchopulmonary
dysplasia †
<0.001213 (21, 18 to 23)48 (11, 8 to 14)73 (21, 17 to 26)63 (36, 29 to 43)28 (42, 30 to 55)1 (33, 1 to 91)Retinopathy stage ≥3 (in at
least one eye)
<0.001166 (16, 14 to 19)39 (9, 6 to 12)57 (7, 13 to 21)48 (27, 21 to 34)22 (33, 22 to 46)0 (0, 0 to 71)Laser treatment for
retinopathy
0.87135 (13, 11 to 15)53 (12, 9 to 15)50 (15, 11 to 19)27 (15, 10 to 21)4 (6, 2 to 15)1 (33, 1 to 91)Severe abnormality on last
available cerebral
ultrasound scan‡
0.02079 (8, 6 to 9)29 (6, 4 to 9)25 (7, 5 to 11)20 (11, 7 to 17)4 (6, 2 to 15)1 (33, 1 to 91)Laparotomy for necrotising
enterocolitis
Other morbidities
z score <−2 at 40 weeks postmenstrual age:
<0.001454 (44, 41 to 48)183 (41, 37 to 46)143 (43, 37 to 48)90 (51, 43 to 58)37 (57, 44 to 69)1 (33, 1 to 91)Weight
<0.001251 (26, 23 to 29)82 (20, 16 to 24)78 (25, 20 to 30)62 (36, 29 to 44)29 (46, 33 to 59)0 (0 to 71)Occipitofrontal
circumference
<0.001500 (51, 46 to 54)168 (41, 36 to 46)162 (49, 44 to 55)118 (68, 61 to 75)50 (77, 65 to 86)2 (67, 9 to 99)Treated patent ductus
arteriosus§
<0.001166 (16, 14 to 18)40 (9, 6 to 12)59 (17, 13 to 22)41 (23, 17 to 30)24 (36, 25 to 49)2 (67, 9 to 99)Patent ductus arteriosus
treated surgically
0.00181 (8, 6 to 10)28 (6, 4 to 9)19 (6, 3 to 9)22 (13, 8 to 18)12 (18, 10 to 30)0 (0, 0 to 71)Gram negative bacteraemia
>72 hours after birth
<0.001514 (50, 47 to 53)189 (43, 38 to 48)179 (52, 47 to 58)106 (61, 53 to 68)37 (56, 43 to 68)3 (100, 29 to 100)Coagulase negative
staphylococcal bacteraemia
>72 hours after birth
0.01836 (4, 2 to 5)8 (2, 1 to 4)17 (5, 3 to 8)9 (5, 2 to 9)2 (3, 0 to 11)0 (0, 0 to 71)Positive fungal blood culture
at any age
<0.001423 (41, 38 to 44)222 (50, 45 to 54)133 (38, 33 to 44)52 (29, 23 to 37)15 (23, 13 to 35)1 (33, 1 to 91)Survival without major
morbidity
*P value for association of gestational age using either logistic regression or regression with gestational age in decimal weeks.
†Severe bronchopulmonary dysplasia defined as still receiving mechanical ventilatory support and/or in ≥30% or >0.1L/min supplementary oxygen.16
‡Severe abnormality on cerebral ultrasonography defined as scan showing one or more of ventriculomegaly, parenchymal cysts, haemorrhagic parenchymal
infarction.
§Patent ductus arteriosus treated with either indometacin, ibuprofen, or surgical ligation
¶Major morbidity defined as any of: severe abnormality on cerebral ultrasonography, severe bronchopulmonary dysplasia, retinopathy of prematurity stage 3 or
more, or laparotomy for necrotising enterocolitis
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Table 3| Population characteristics of admissions to intensive care of babies born between 22 and 25 weeks’ gestation in England in
EPICure (March to December 1995) and EPICure 2 (January to December 2006) cohorts. Figures are numbers (percentages) unless stated
otherwise
Difference
(95 CI)
EPICure 2
(n=1115)
EPICure
(n=666)
2.5 (−2 to 7)821 (74)474 (71)Singletons
−2 (−7 to 3)580 (52)357 (54)Male
−2 g (−14 g to 10 g)‡697 (610-779)695 (620-787)Median (IQR) birth weight (g)†
Maternal ethnicity:
−9 (−13 to −5)***728 (65)495 (74)White
4 (0 to 8)*216 (19)103 (16)Afro-Caribbean
4 (1 to 6)**117 (11)45 (7)Indian subcontinent
1.5 (0 to 3)37 (3)12 (2)Other
0 (−1 to 1)17 (2)11 (2)Missing
Obstetric problems:
1.5 (0 to 3)52/1110 (5)21/659 (3)Pre-eclampsia
3 (−1 to 7.5)306/1110 (27)160/659 (24)Membranes ruptured >24 hours
−2 (−4 to 1)81/1110 (7)59/659 (9)Cervical suture
−7 (−11 to −3)***216/1112 (20)176/659 (27)Antepartum haemorrhage
4 (0 to 8)*248/1081 (23)123/659 (19)Clinical diagnosis of chorioamnionitis
14 (10 to 19)***911/1108 (82)448/661 (68)Any antenatal steroid
9 (4 to 13)***551/1104 (50)273/661 (41)Antenatal steroid >24 hours before birth
7 (2 to 11)**369/1109 (33)174/652 (27)Maternal tocolysis
2 (−1 to 6)221/1113 (20)117/665 (18)Caesarean section
5 (1 to 8)**985/1086 (91)556/645 (86)Heart rate >100 at 5 min
−24 (−28 to −19)***187/1091 (17)255/626 (41)Admission temp <35°C
5 (1 to 8)*225/1115 (20)103/665 (16)Transfer within 24 hours of birth
12 (10 to 15)***1102/1115 (99)574/664 (86)Surfactant at any time
−2 (−3 to −2)‡***9 (5-11, 1-23)11 (8-14, 1-22)Median (IQR, range) CRIB I score
IQR=interquartile range.
*P≤0.05, ** P≤0.01, *** P≤0.001.
†Missing for one baby from 2006 cohort.
‡Difference in means.
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Table 4| Principal causes of death of babies admitted for intensive care in those born between 22 and 25 weeks’ gestation in England in
EPICure (March to December 1995) and EPICure 2 (January to December 2006) cohorts. Figures are numbers (percentages)
% Difference (95% CI)EPICure 2 (n=522)EPICure (n=400)
−1 (−2 to 1)4 (1)6 (2)Congenital malformation
−13 (−19 to −8)***85 (16)119 (30)Pulmonary insufficiency
2 (−4 to 8)174 (33)125 (31)Respiratory distress syndrome/intracerebral
haemorrhage/infection
−2 (−5 to 2)40 (8)37 (9)Late sequelae of ventilation
8 (4 to 12)***84 (16)32 (8)Infection
2 (−1 to 5)33 (6)17 (4)Intracranial haemorrhage
9 (6 to 12)***63 (12)12 (3)Necrotising enterocolitis
−4 (−8 to 0)*35 (7)42 (11)Other†
−2 (−3 to 0)*4 (1)10 (3)Not known
*P≤0.05, ** P≤0.01, *** P≤0.001.
†In 2006 “other” deaths included pulmonary haemorrhage (n=18), renal failure (n=5), pulmonary hypoplasia (n=3), air leak and thromboembolism (n=2 of each),
and one each of twin to twin transfusion, refractory hypotension, late encephalopathy, and operative complication of ligation of patent ductus arteriosus.
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Table 5| Predictive multivariable models for inpatient deaths and four major neonatal morbidities in survivors born at 22-25 weeks’ gestation
in 1995 and 2006. Figures are odds ratios (95% confidence intervals)
Survivors (n=266 in 1995 and 593 in 2006)Death before discharge
for all admissions
Laser treatment for
retinopathy§
Supplementary oxygen
at 40 weeks PMA
Bronchopulmonary
dysplasia (supplementary
oxygen at 36 weeks PMA)
Severe abnormality†
on cerebral scan‡
(n=666 in 1995 and 1115
in 2006)*
8518218308471630Total No included
2.90 (1.71 to 4.92)1.12 (0.81 to 1.56)1.04 (0.72 to 1.50)1.17 (0.74 to 1.85)1.10 (0.85 to 1.43)2006 v 1995
Significant clinical associates in combined cohorts:
0.50 (0.37 to 0.67)0.61 (−0.47 to 0.80)0.62 (0.45 to 0.85)—0.73 (0.62 to 0.86)Gestational age (per
week)
0.71 (0.53 to 0.06)0.73 (0.57 to 0.92)0.69 (0.52 to 0.91)—Birth weight (per SD)
—1.76 (1.31 to 2.36)2.08 (1.48 to 2.91)—1.60 (1.27 to 2.01)Male
————0.61 (0.46 to 0.82)Chorioamnionitis
———0.55 (0.37 to 0.82)0.68 (0.53 to 0.86)Antenatal steroid¶
—1.51 (1.12 to 2.04)———Tocolysis
0.26 (0.15 to 0.46)——0.48 (0.27 to 0.86)—Afro-Caribbean ethnicity
————0.58 (0.43 to 0.78)Vaginal delivery
————0.56 (0.37 to 0.84)Heart rate >100 at 5 min
—0.64 (0.42 to 0.98)0.57 (0.33 to 0.98)—0.75 (0.56 to 1.00)Admission temperature
≥35°C
CRIB 1 score** (per point):
—1.07 (1.01 to 1.13)1.08 (1.00 to 1.15)——Combined cohort
————1.32 (1.24 to 1.40)1995 cohort only
1.10 (1.02 to 1.18)———1.22 (1.17 to 1.27)2006 cohort only
PMA=postmenstrual age.
*Odds ratios additionally adjusted for antepartum haemorrhage in 2006 cohort (OR 0.62, 95%CI 0.43 to 0.88). Interaction of CRIB I with cohort is significant hence
values for separate cohorts are given.
†Defined as last available cerebral ultrasound scan with any of ventriculomegaly, parenchymal cysts, haemorrhagic parenchymal infarct.
‡Odds ratios additionally adjusted for transfer within 24 hours of birth in 1995 cohort only(OR 3.08, 95%CI 1.36 to 6.96).
§Odds ratios additionally adjusted for antepartum haemorrhage in 1995 cohort only (OR 2.74, 95%CI 1.28 to 5.88).
¶Antenatal steroid given to mother >24 hours before birth.
**Clinical risk index for babies (CRIB I),19 centred on mean score (9.5) of combined admitted cohorts and to zero in both individual year cohorts.
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Figures
Fig 1 Survival curves by gestational age (23-25 weeks) up to 120 days postnatal age for all babies admitted to neonatal
intensive care and those surviving seven days. Each graph shows percentage (95% CI) change in survival to discharge
Fig 2Changes in important neonatal morbidities for babies born at 25 weeks’ gestation or less in 1995 and 2006 in England.
Figures above bars show % change (95% confidence interval) from 1995 to 2006
Fig 3 Changes in postnatal occipitofrontal circumference and weight z scores from birth to expected date of delivery (EDD)
at discharge from hospital for babies born at 25 weeks of gestation or less in 1995 and 2006 in England. Figures above
bars show SD change (95% confidence interval) from 1995 to 2006
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